Unknown

Dataset Information

0

Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report.


ABSTRACT: More than half of patients with high-risk neuroblastoma (HR-NB) experience relapse/regrowth due to the activation of chemoresistant minimal residual disease (MRD). MRD in patients with HR-NB can be evaluated by quantitating neuroblastoma-associated mRNAs (NB-mRNAs) in bone marrow (BM) and peripheral blood (PB) samples. Although several sets of NB-mRNAs have been shown to possess a prognostic value for MRD in BM samples (BM-MRD), MRD in PB samples (PB-MRD) is considered to be low and difficult to evaluate. The present report describes an HR-NB case presenting higher PB-MRD than BM-MRD before 1st and 2nd relapse/regrowth. A 3-year-old female presented with an abdominal mass, was diagnosed with HR-NB, and treated according to the nationwide standard protocol for HR-NB. Following systemic induction and consolidation therapy with local therapy, the patient achieved complete remission but experienced a 1st relapse/regrowth 6 months after maintenance therapy. The patient partially responded to salvage chemotherapy and anti-GD2 immunotherapy but had a 2nd relapse/regrowth 14 months after the 1st relapse/regrowth. Consecutive PB-MRD and BM-MRD monitoring revealed that PB-MRD was lower than BM-MRD at diagnosis (100 times) and 1st and 2nd relapse/regrowth (1,000 and 3 times) but became higher than BM-MRD before 1st and 2nd relapse/regrowth. The present case highlights that PB-MRD can become higher than BM-MRD before relapse/regrowth of patients with HR-NB.

SUBMITTER: Inoue S 

PROVIDER: S-EPMC10407720 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report.

Inoue Shotaro S   Win Kaung Htet Nay KHN   Mon Cho Yee CY   Fujikawa Tomoko T   Hyodo Sayaka S   Uemura Suguru S   Ishida Toshiaki T   Mori Takeshi T   Hasegawa Daiichiro D   Kosaka Yoshiyuki Y   Nishimura Akihiro A   Nakatani Naoko N   Nino Nanako N   Tamura Akihiro A   Yamamoto Nobuyuki N   Nozu Kandai K   Nishimura Noriyuki N  

Oncology letters 20230714 3


More than half of patients with high-risk neuroblastoma (HR-NB) experience relapse/regrowth due to the activation of chemoresistant minimal residual disease (MRD). MRD in patients with HR-NB can be evaluated by quantitating neuroblastoma-associated mRNAs (NB-mRNAs) in bone marrow (BM) and peripheral blood (PB) samples. Although several sets of NB-mRNAs have been shown to possess a prognostic value for MRD in BM samples (BM-MRD), MRD in PB samples (PB-MRD) is considered to be low and difficult to  ...[more]

Similar Datasets

| S-EPMC8138775 | biostudies-literature
| S-EPMC10119313 | biostudies-literature
| S-EPMC2670609 | biostudies-literature
| S-EPMC1867438 | biostudies-literature
| S-EPMC9751059 | biostudies-literature
| S-EPMC9172186 | biostudies-literature
| S-EPMC11252770 | biostudies-literature
| S-EPMC8145602 | biostudies-literature
| S-EPMC6826431 | biostudies-literature
| S-EPMC8945288 | biostudies-literature